Consolidated Financial Results for the Nine Months Ended September 30, 2026 (Under Japanese GAAP)

November 2, 2026

Company name CREATE MEDIC CO., LTD.
Stock exchange listings：Tokyo Standard
Securities code 5187
URL https://www.createmedic.co.jp/english/
Representative Osamu Imazawa President
Inquiries Teruya Ueno Executive Officer, General Manager of Corporate Planning Department

Dividend payable date (as planned) ：—
Supplemental material of results：Yes, only in Japanese
Convening briefing of results ：None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended September 30, 2026 (from January 1, 2026 to September 30, 2026)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	10,467	4.1	509	(44.2)	568	(34.8)	301	(54.7)
September 30, 2025	10,054	5.7	913	75.3	871	59.9	666	(10.5)

Note: Comprehensive income For the nine months ended September 30, 2026：699 Millions of yen (82.8%)
For the nine months ended September 30, 2025：382 Millions of yen ((57.0)%)

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
September 30, 2026	37.05	33.30
September 30, 2025	78.45	76.57

(2) Consolidated financial position

	Total assets	Net assets	Capital adequacy ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
September 30, 2026	19,831	16,148	81.4	2,028.71
December 31, 2025	20,143	16,332	81.1	1,947.68

Reference: Owner's equity As of September 30, 2026 16,147 Millions of yen
As of December 31, 2025 16,331 Millions of yen

2. Cash dividends

	Annual dividend				
	First quarter	Second quarter	Third quarter	Year end	Annual
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2025	—	17.00	—	28.00	45.00
Fiscal year ending December 31, 2026	—	20.00	—		
Fiscal year ending December 31, 2026 (Forecast)				27.00	47.00

Note: Revisions to the forecast of cash dividends most recently announced：None

3. Consolidated financial forecast for the fiscal year ending December 31, 2026 (from January 1, 2026 to December 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
Fiscal year ending	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
December 31, 2026	13,960	2.5	760	(24.4)	800	(19.0)	560	(21.5)	68.90

Note: Revisions to the earnings forecasts most recently announced：None

* Notes

(1) Significant changes in the scope of consolidation during the period：None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements：None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations ：None

(ii) Changes in accounting policies due to other reasons ：None

(iii) Changes in accounting estimates ：None

(iv) Restatement ：None

(4) Number of issued shares (common shares)

① Number of issued and outstanding shares at the period end (including treasury stock)	As of September 30, 2026	9,664,327shares	As of December 31, 2025	9,664,327shares
② Number of treasury stock at the period end	As of September 30, 2026	1,704,726shares	As of December 31, 2025	1,279,220shares
③ Average number of shares (quarterly period-YTD)	Nine months ended September 30, 2026	8,146,383shares	Nine months ended September 30, 2025	8,497,339shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm：None

* Proper use of earnings forecasts, and other special matters

Caution Regarding Forward-Looking Statements:

The forward-looking statements contained in this document are based on information currently available to the Company and certain assumptions that the Company deems to be reasonable. They are not intended as a promise by the Company that they will be achieved, and actual results may differ significantly due to various factors.